SCHEMBL30528804

SCHEMBL30528804

Cc1cc(-c2cncc(C(F)(F)F)n2)ccc1NC(=O)C(C)(C)c1ccnc(NS(=O)(=O)C2CC2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CTPS1 P17812 20/20 1.00
▸ CTPS2 Q9NRF8 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373848 1.00 CTPS1 (1.00) CTPS1CTPS2
SCHEMBL30528878 0.92 CTPS1 (0.85) CTPS1CTPS2
SCHEMBL21373751 0.92 CTPS1 (0.85) CTPS1CTPS2
SCHEMBL21373803 0.90 CTPS1 (1.00) CTPS1CTPS2
SCHEMBL30528967 0.90 CTPS1 (1.00) CTPS1CTPS2
SCHEMBL21373799 0.88 CTPS1 (0.80) CTPS1
SCHEMBL30528779 0.87 CTPS1 (0.81) CTPS1CTPS2
SCHEMBL21373690 0.87 CTPS1 (0.81) CTPS1CTPS2
SCHEMBL21387645 0.86 CTPS1 (0.75) CTPS1CTPS2
SCHEMBL22491661 0.84 CTPS1 (0.85) CTPS1CTPS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4637770-A1 CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER Step Pharma S.A.S. (FR) 2025-10-29 — — EP disclosed
EP-4486347-A1 COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER Step Pharma S.A.S. (FR) 2025-01-08 — — EP disclosed
CN-118804752-A Combination of CTPS1 and BCL2 inhibitors for the treatment of cancer 斯泰普制药股份公司 2024-10-18 — — CN disclosed
WO-2024133721-A1 COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER STEP PHARMA S.A.S. (FR) 2024-06-27 — — WO disclosed
CN-111868051-B Aminopyrimidine derivatives as CTPS1 inhibitors 斯泰普制药股份公司 2024-04-09 — — CN disclosed
WO-2023166076-A1 COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER STEP PHARMA S.A.S. (FR) 2023-09-07 — — WO disclosed
WO-2023166080-A1 COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A WEE1 INHIBITOR STEP PHARMA S.A.S. (FR) 2023-09-07 — — WO disclosed
WO-2023166077-A1 COMBINATION OF A CTPS1 INHIBITOR AND A ATR INHIBITOR IN CANCER THERAPY STEP PHARMA S.A.S. (FR) 2023-09-07 — — WO disclosed
WO-2023166078-A1 COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR STEP PHARMA S.A.S. (FR) 2023-09-07 — — WO disclosed
Send feedback